Global Veterinary Ketamine Hydrochloride Market Report: Trends & Opportunities, 2018 - 2030

Deliverable Overview

The animal health team at Grand View Research has estimated and forecasted a trend report of the veterinary ketamine hydrochloride (KHCl) market for key regions and countries from 2018 to 2030. The trend report comprises market revenue in USD million as well as sales volume in KGs. It covers leading countries across North America, Europe, Asia Pacific, Latin America, and MEA. These countries represent key markets where animal population, expenditure, pet humanization, and the adoption of pet insurancewere estimated to be the highest.

Report Overview

The global veterinary ketamine hydrochloride market size was estimated at USD 12.69 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 2.81% from 2024 to 2030. This can be attributed to Ketamine Hydrochloride (KHCl) being the drug of choice for induction and, at times, for upkeep of anesthesia in animals, considering its wide applicability in terms of target species, and the associated benefits.

For instance, KHCL is a widely adopted anesthetic for a range of animal species, including dogs, cats, horses, livestock, laboratory research animals, sub-human primates, and wild animals in zoos & national parks. In addition, as per the British Association for Psychopharmacology, ketamine is one of the most widely used anesthetics in veterinary practices and is also used to provide pain relief in certain circumstances.

The availability of KHCL drugs from leading companies, such as Zoetis, Dechra, Ceva Santé Animale, Chanelle Pharma, Boehringer Ingelheim International GmbH, & Covetrus, contributes to the market revenue. Strategic initiatives comprising partnerships & collaborations, mergers & acquisitions, and regional/portfolio expansions undertaken by established and emerging players are expected to propel market growth over the forecast period.

In 2020, Bela-Pharm GmbH & Co. KG, for example, received expanded species approval for its Ketamine 10% product-Ketabel 100 mg/ml. With this, the company has commercially launched the product for a total of 12 target species, including dogs, cats, pigs, horses, sheep, goats, rabbits, rats, cattle, guinea pigs, hamsters, and mice. The product has been launched in the following European countries: Austria, Czech Republic, Germany, Greece, Hungary, Iceland, Ireland, Estonia, Finland, France, Latvia, Lithuania, Norway, Portugal, Romania, Slovenia, Slovakia, The Netherlands, and the UK.

The report covers a detailed list of Veterinary Ketamine Hydrochloride API manufacturers. Some of the key players included in the analysis are:

• Biosynth

• Seqens

• Chemopharma Group

Furthermore, the report covers a list of potential customers of Veterinary Ketamine Hydrochloride API. These include animal health companies with existing commercial veterinary KHCl products as well as animal health companies catering to the veterinary anesthetics segment in general. Some of the key potential customers include:

• Dechra

• Zoetis

• Boehringer Ingelheim International GmbH

• Covetrus

• Ceva Santé Animale

• Chanelle Pharma

Regional Insights

By region, North America accounted for the largest share in 2023. Key factors contributing to the significant share include the presence of key companies, advanced veterinary healthcare infrastructure, wide uptake of KHCl in veterinary anesthesia, high animal health expenditure, and increasing medicalization rate across North American. Middle East & Africa, on the other hand, is anticipated to register the fastest CAGR of about 6.28% from 2024 to 2030.

Veterinary ketamine hydrochloride (KHCL) finds wide adoption in veterinary anesthesia owing to the following benefits:

• Does not need intravenous access and can be given intramuscularly, thus adding to its safety and efficacy

• Respiratory and cardiovascular systems are not depressed when recommended doses are administered, making it safe for use by relatively inexperienced personnel. This enhances its safety profile

• Drug of choice for administering ketamine/sedative combination anesthesia via dart gun to members of the cat family (e.g., tigers, lions, etc.) in zoos and in the wild 

  

Veterinary Ketamine Hydrochloride Market Report Scope